Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.45 |
| ▸ | CTSS | P25774 | 9/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8135865 | 0.87 | CTSS (0.41) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL3309119 | 0.87 | CTSS (0.43) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL13505875 | 0.84 | CTSK (0.44) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL13505874 | 0.84 | CTSK (0.44) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL1854385 | 0.81 | KDM4E (0.37) | CTSL | |
| SCHEMBL4098402 | 0.78 | CTSS (0.41) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL3314258 | 0.76 | NPFFR1 (0.39) | — | |
| SCHEMBL15772496 | 0.74 | CTSS (0.44) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL15772497 | 0.74 | CTSS (0.44) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL15772114 | 0.73 | HDAC8 (0.42) | CTSKCTSSCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030118-B2 | Pyrrolotriazinone compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1519729-A1 | PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003099286-A1 | PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | CCNB1, NUMA1, CCNA1 | CTSK 3686/4885CTSS 3851/4885CTSL 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.